Strategy
We strive to foster the creation of important new treatments for patients.
We follow a multi-pronged strategy with investments at all stages of product development across multiple disease areas.
Investment appetite
Our portfolio is driven by patients in need, and opportunities to develop and commercialise important new treatment options for them. Our typical investment criterion are outlined in the box to the right.
Discover our portfolio- Typical Investment Size
- $15-$30mIn total per company
- Geography
- Primarily US & Europe
- Holding Period
- 3-8 years
- Sectors
Biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, cell therapies, specialty pharma, platform technologies.
- Typical Investment Size
- Min. $30m per companyMay be combined with equity in a hybrid financing solution
- Geography
- Global
- Holding Period
- 2 – 10 yearsSeek accelerated return through monetisation
- Focus
Pivotal stage biotherapeutics including small molecules, nucleic acid therapeutics, vaccines, gene therapies and cell therapies.
Broad Strategic Approach
Biopharma companies in need of capital come with many different profiles. Some are startups seeking to discover new drugs based on emerging insights into underlying mechanisms of disease. Others may have begun that way, but now have drugs in clinical trials. Many are still privately held, while others are publicly traded. Some may even be established pharmaceutical companies looking for creative ways to fund expensive clinical trials.
Our strategies, described below, are designed to help companies in all these categories pursue their goal of developing novel and effective therapies for patients.
